

DAFTAR PUSTAKA

- Abraham, P., Avenell, A., McGeoch, S. C., Clark, L. F., & Bevan, J. S. (2010). Antithyroid drug regimen for treating Graves' hyperthyroidism. *Cochrane Database of Systematic Reviews*. <https://doi.org/10.1002/14651858.cd003420.pub4>
- Ain, K & Rosenthal, M. S. (2011). Graves' Disease. In *The Complete Thyroid Book* (pp. 97-107). McGraw-Hill
- Bartalena, L., Burch, H. B., Burman, K. D., & Kahaly, G. J. (2016). A 2013 European survey of clinical practice patterns in the management of Graves' disease. *Clinical Endocrinology*, 84(1), 115–120. <https://doi.org/10.1111/cen.12688>
- Bartalena, Luigi. (2013). Diagnosis and management of Graves disease: A global overview. In *Nature Reviews Endocrinology* (Vol. 9, Issue 12, pp. 724–734). <https://doi.org/10.1038/nrendo.2013.193>
- Brent, G. A. (2008). Graves' disease. *New England Journal of Medicine*, 358(24), 2594–2605. <https://doi.org/10.1056/NEJMcp0801880>
- Brito, J. P., Schilz, S., Singh Ospina, N., Rodriguez-Gutierrez, R., Maraka, S., Sangaralingham, L. R., & Montori, V. M. (2016). Antithyroid Drugs - The Most Common Treatment for Graves' Disease in the United States: A Nationwide Population-Based Study. In *Thyroid* (Vol. 26, Issue 8, pp. 1144–1145). Mary Ann Liebert Inc. <https://doi.org/10.1089/thy.2016.0222>
- Cooper, D. S. (2005). Antithyroid drugs. In *New England Journal of Medicine* (Vol. 352, Issue 9, pp. 905–917). <https://doi.org/10.1056/NEJMra042972>
- Cooper, D. S. & Burman, K. D. (2008). Hyperthyroidism Due to Graves' Disease, Toxic Nodules and Toxic Multinodular Goiter. In *Medical Management of Thyroid Disease* (pp. 39-83). Informa Healthcare USA
- De Leo, S., Lee, S. Y., & Braverman, L. E. (2016). Hyperthyroidism. In *The Lancet* (Vol. 388, Issue 10047, pp. 906–918). Lancet Publishing Group. [https://doi.org/10.1016/S0140-6736\(16\)00278-6](https://doi.org/10.1016/S0140-6736(16)00278-6)
- De los Santos, E. T. (1989). Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. *Archives of Internal Medicine*, 149(3), 526–532. <https://doi.org/10.1001/archinte.149.3.526>

- El-Kaissi, S., Frauman, A. G., & Wall, J. R. (2004). Thyroid-associated ophthalmopathy: a practical guide to classification, natural history and management. *Internal Medicine Journal*, 34(8), 482–491. <https://doi.org/10.1111/j.1445-5994.2004.00662.x>
- Emiliano, A. B., Governale, L., Parks, M., & Cooper, D. S. (2010). Shifts in propylthiouracil and methimazole prescribing practices: Antithyroid drug use in the United States from 1991 to 2008. *Journal of Clinical Endocrinology and Metabolism*, 95(5), 2227–2233. <https://doi.org/10.1210/jc.2009-2752>
- Ginsberg, J. (2003). Diagnosis and management of Graves' disease. *CMAJ: Canadian Medical Association Journal = Journal de l'Association Medicale Canadienne*, 168(5), 575–585. <http://www.ncbi.nlm.nih.gov/pubmed/12615754>
- Girgis, C. M., Champion, B. L., & Wall, J. R. (2011). Current concepts in Graves' disease. In *Therapeutic Advances in Endocrinology and Metabolism* (Vol. 2, Issue 3, pp. 135–144). <https://doi.org/10.1177/2042018811408488>
- He, C.-T., Hsieh, A.-T., Pei, D., Hung, Y.-J., Wu, L.-Y., Yang, T.-C., Lian, W.-C., Huang, W.-S., & Kuo, S.-W. (2004). Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism. *Clinical Endocrinology*, 60(6), 676–681. <https://doi.org/10.1111/j.1365-2265.2004.02032.x>
- Ishtiaq, O.; Waseem, S.; Haque, MN; Islam, N.; Jabbar, A. (2009). Remission of Graves' Disease After Oral Anti-Thyroid Drug Treatment. *Journal of the College of Physicians and Surgeons Pakistan*, 19(11), 690–693.
- Kahaly, G. J., Bartalena, L., Hegedüs, L., Leenhardt, L., Poppe, K., & Pearce, S. H. (2018). 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. *European Thyroid Journal*, 7(4), 167–186. <https://doi.org/10.1159/000490384>
- Leslie, W. D., Ward, L., Salamon, E. A., Ludwig, S., Rowe, R. C., & Cowden, E. A. (2003). A Randomized Comparison of Radioiodine Doses in Graves' Hyperthyroidism. *The Journal of Clinical Endocrinology & Metabolism*, 88(3), 978–983. <https://doi.org/10.1210/jc.2002-020805>
- Nakamura, H., Miyauchi, A., Miyawaki, N., & Imagawa, J. (2013). Analysis of 754 Cases of Antithyroid Drug-Induced Agranulocytosis Over 30 Years in Japan. *The Journal of Clinical Endocrinology & Metabolism*, 98(12), 4776–4783. <https://doi.org/10.1210/jc.2013-2569>
- Pearce, S. H. S. (2004). Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. *Clinical Endocrinology*, 61(5), 589–594. <https://doi.org/10.1111/j.1365-2265.2004.02135.x>

- Pusat Data dan Informasi Kesehatan RI. (2015). Bebaskan Dirimu dari Gangguan Tiroid. *Infodatin*, 1-7
- Rapoport, B., & McLachlan, S. M. (2007). The thyrotropin receptor in Graves' disease. In *Thyroid* (Vol. 17, Issue 10, pp. 911–922). <https://doi.org/10.1089/thy.2007.0170>
- Rosenblum, M. D., Remedios, K. A., & Abbas, A. K. (2015). Mechanisms of human autoimmunity. *Journal of Clinical Investigation*, 125(6), 2228–2233. <https://doi.org/10.1172/JCI78088>
- Sastroasmoro, S. (2011). Dasar-dasar Metodologi Penelitian Klinis. *Dalam: Sagung Seto*
- Smith, T. J., & Hegedüs, L. (2016). Graves' disease. In *New England Journal of Medicine* (Vol. 375, Issue 16, pp. 1552–1565). Massachussetts Medical Society. <https://doi.org/10.1056/NEJMra1510030>
- Spencer, C. A., Lopresti, J. S., Patel, A., Guttler, R. B., Eigen, A., Shen, D., Gray, D., & Nicoloff, J. T. (1990). Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. *Journal of Clinical Endocrinology and Metabolism*, 70(2), 453–460. <https://doi.org/10.1210/jcem-70-2-453>
- Stenszky, V., Kozma, L., Balazs, C., Rochlitz, S., Bear, J. C., Farid, & N. R. (1985). The Genetics of Graves' Disease: HLA and Disease Susceptibility*. *The Journal of Clinical Endocrinology & Metabolism*, 61(4), 735–740. <https://doi.org/10.1210/jcem-61-4-735>
- Sugiyono (2013). Metode Penelitian Kuantitatif, Kualitatif, dan R&D. *Alfabeta*
- Wang, Y., Yin, Q., Xu, M., Ni, Q., Wang, W., & Wang, Q. (2017). BMI Modulates the Effect of Thyroid Hormone on Lipid Profile in Euthyroid Adults. *International Journal of Endocrinology*, 2017. <https://doi.org/10.1155/2017/8591986>
- Wartofsky, L., Glinioer, D., Solomon, B., Nagataki, S., Lagasse, R., Nagayama, Y., & Izumi, M. (1991). Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. *Thyroid : Official Journal of the American Thyroid Association*, 1(2), 129–135. <https://doi.org/10.1089/thy.1991.1.129>
- Yang, J., Zhu, Y.-J., Zhong, J.-J., Zhang, J., Weng, W.-W., Liu, Z.-F., Xu, Q., & Dong, M.-J. (2016). Characteristics of Antithyroid Drug–Induced Agranulocytosis in Patients with Hyperthyroidism: A Retrospective Analysis of 114 Cases in a Single Institution in China Involving 9690 Patients Referred for Radioiodine Treatment Over 15 Years. *Thyroid*, 26(5), 627–633. <https://doi.org/10.1089/thy.2015.0439>